Forkhead box P3 (FOXP3) is constitutively expressed by CD4(+)CD25(hi) regulatory T cells (nTregs). Mutations of FOXP3 cause a severe autoimmune syndrome known as immune dysregulation polyendocrinopathy enteropathy X-linked, in which nTregs are absent or dysfunctional. Whether FOXP3 is essential for both differentiation and function of human nTreg cells remains to be demonstrated. Because FOXP3 is an X-linked gene subject to X-chromosome inactivation (XCI), we studied 9 healthy female carriers of FOXP3 mutations to investigate the role of wild-type (WT) versus mutated FOXP3 in different cell subsets. Analysis of active WT versus mutated (mut)-FOXP3 allele distribution revealed a random pattern of XCI in peripheral blood lymphocytes and in naive and memory CD4(+)T cells, whereas nTregs expressed only the active WT-FOXP3. These data demonstrate that expression of WT-FOXP3 is indispensable for the presence of a normal nTreg compartment and suggest that FOXP3 is not necessary for effector T-cell differentiation in humans.

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2009-04-214593DOI Listing

Publication Analysis

Top Keywords

cd4+cd25hi regulatory
8
regulatory cells
8
healthy female
8
female carriers
8
foxp3
8
carriers foxp3
8
foxp3 mutations
8
cells ntregs
8
versus mutated
8
wild-type foxp3
4

Similar Publications

Article Synopsis
  • Lanthionine synthetase C-like 2 (LANCL2) is identified as a key immunoregulatory target in treating autoimmune diseases like systemic lupus erythematosus (SLE), with the investigational drug NIM-1324 aimed at improving patient outcomes.
  • In laboratory models, mice lacking LANCL2 exhibited severe symptoms of inflammation, while treatment with NIM-1324 enhanced regulatory T cell populations and reduced harmful inflammatory T cells, leading to overall better health markers.
  • NIM-1324 also showed efficacy in human immune cells from SLE patients, lowering pro-inflammatory cytokines and supporting a more balanced immune response, indicating its potential as a therapeutic option.
View Article and Find Full Text PDF

Background/aim: We herein examined T cell immunity in esophageal cancer patients with and without Helicobacter pylori infection to establish a foundation for immunotherapeutic strategies targeting esophageal cancer in the presence of H. pylori infection.

Materials And Methods: Twenty-six patients with esophageal squamous cell carcinoma between 2015 and 2017 were enrolled in the present study.

View Article and Find Full Text PDF

The Biologic IRL201805 Alters Immune Tolerance Leading to Prolonged Pharmacodynamics and Efficacy in Rheumatoid Arthritis Patients.

Int J Mol Sci

April 2024

Academic Department of Rheumatology, Centre for Inflammation Biology and Cancer Immunology (CIBCI), King's College London Faculty of Life Sciences and Medicine, Guy's Hospital Campus, London SE1 1UL, UK.

A homologue of binding immunoglobulin protein/BiP-IRL201805 alters the function of immune cells in pre-clinical in vivo and in vitro studies. The aim of the study was to select biomarkers that clearly delineate between RA patients who respond to IRL201805 and placebo patients and reveal the immunological mode of action of IRL201805 driving the extended pharmacodynamics observed in responding patients. Biomarkers that distinguished between responding patients and placebo patients included downregulation of serum interferon-γ and IL-1β; upregulation of anti-inflammatory mediators, serum soluble CTLA-4, and intracellular monocyte expression of IDO; and sustained increased CD39 expression on CD3CD4CD25 CD127 regulatory T cells.

View Article and Find Full Text PDF

Background And Objectives: Hashimoto's thyroiditis (HT), a chronic autoimmune disorder impacting thyroid function, is a growing public health concern. The relationship between Treg cells and HT has been extensively studied, with Treg cells considered crucial in suppressing HT progression. However, these studies have mainly been observational, limiting our understanding of Treg cells' impact on HT risk.

View Article and Find Full Text PDF

Regulatory T-cell frequency and function in acute myocardial infarction patients and its correlation with ventricular dysfunction.

Clin Exp Immunol

May 2024

Medicina Molecular y Traslacional, Centro de Investigación en Ciencias de la Salud y Biomedicina, Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, México.

A high percentage of patients with acute coronary syndrome develop heart failure due to the ischemic event. Regulatory T (Treg) cells are lymphocytes with suppressive capacity that control the immune response and include the conventional CD4+ CD25hi Foxp3+ cells and the CD4+ CD25var CD69+ LAP+ Foxp3- IL-10+ cells. No human follow-up studies focus on Treg cells' behavior after infarction and their possible relationship with ventricular function as a sign of postischemic cardiac remodeling.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!